BiologicalDrug
Lyophilized Inactivated Group A Streptococcus TARA-002 clinical trials
- studies test it
- 5
- open now
- 3
- in phase 3
- 1
- first study started
- 2022
Keep track of what changes. Save the Lyophilized Inactivated Group A Streptococcus TARA-002 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Protara Therapeutics (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Lyophilized Inactivated Group A Streptococcus TARA-002 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruitingPhase 3Protara TherapeuticsNCT07480356Written as TARA-002
- Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerRecruitingPhase 2Protara TherapeuticsNCT05951179Written as TARA-002
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeRecruitingPhase 2Protara TherapeuticsNCT05871970Written as TARA-002
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)CompletedPhase 1Protara TherapeuticsNCT05085990Written as TARA-002
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)CompletedPhase 1Protara TherapeuticsNCT05085977Written as TARA-002